| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CLDN3 |
| Uniprot No | O15551 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-220aa |
| 氨基酸序列 | MSMGLEITGTALAVLGWLGTIVCCALPMWRVSAFIGSNIITSQNIWEGLWMNCVVQSTGQMQCKVYDSLLALPQDLQAARALIVVAILLAAFGLLVALVGAQCTNCVQDDTAKAKITIVAGVLFLLAALLTLVPVSWSANTIIRDFYNPVVPEAQKREMGAGLYVGWAAAALQLLGGALLCCSCPPREKKYTATKVVYSAPRSTGPGASLGTGYDRKDYV |
| 预测分子量 | 26.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CLDN3重组蛋白的3篇参考文献示例(内容基于模拟文献)：
---
1. **文献名称**：*Recombinant CLDN3 Protein Enhances Epithelial Barrier Function in vitro*
**作者**：Smith A, et al.
**摘要**：本研究通过大肠杆菌表达系统成功纯化CLDN3重组蛋白，并证明其在体外模型中能够增强上皮细胞屏障的完整性，降低通透性，为治疗肠道屏障功能障碍提供潜在策略。
---
2. **文献名称**：*CLDN3 Overexpression in Ovarian Cancer and Its Role in Chemoresistance*
**作者**：Zhang Y, et al.
**摘要**：通过重组CLDN3蛋白实验，发现其在卵巢癌细胞中过表达会激活PI3K/AKT通路，导致顺铂耐药性增加，提示CLDN3可能作为癌症治疗的新靶点。
---
3. **文献名称**：*Structural Characterization of Recombinant CLDN3 Using Cryo-EM*
**作者**：Tanaka K, et al.
**摘要**：利用冷冻电镜解析了CLDN3重组蛋白的高分辨率结构，揭示了其跨膜结构域的关键氨基酸相互作用，为设计靶向CLDN3的调控分子奠定基础。
---
**注**：以上文献为示例，实际文献需通过PubMed、Google Scholar等平台检索关键词(如“CLDN3 recombinant protein”“CLDN3 structure/function”)。
Claudin-3 (CLDN3) is a key component of tight junction complexes, which are critical for maintaining cell polarity and regulating paracellular transport across epithelial and endothelial barriers. As a member of the claudin family, CLDN3 is a 22-23 kDa transmembrane protein characterized by four transmembrane domains, two extracellular loops, and intracellular N- and C-termini. It plays a pivotal role in forming selective permeability barriers, particularly in tissues such as the kidney, liver, and gastrointestinal tract. Dysregulation of CLDN3 expression has been linked to pathological conditions, including cancer metastasis, inflammatory bowel disease, and compromised epithelial integrity.
Recombinant CLDN3 protein is engineered using DNA recombination technology, often expressed in mammalian or bacterial systems to ensure proper folding and post-translational modifications. This engineered protein retains functional domains necessary for studying its interactions with other tight junction proteins (e.g., occludin, ZO-1) or pathogens targeting epithelial surfaces. Researchers utilize recombinant CLDN3 to investigate its role in cell adhesion, barrier function, and signaling pathways, as well as to develop therapeutic antibodies or inhibitors for diseases associated with claudin dysregulation.
In cancer biology, CLDN3 is overexpressed in certain malignancies (e.g., ovarian, prostate cancers) and may serve as a biomarker or therapeutic target. Its recombinant form facilitates in vitro and in vivo studies to explore mechanisms of tumor progression or drug resistance. Additionally, recombinant CLDN3 aids in elucidating its dual role in inflammation—both as a protective barrier component and a potential mediator of immune cell trafficking. Standardized production of this protein supports reproducibility in research, bridging structural insights to clinical applications.
×
